Evidence map›Paper›PMID 32297787›Full record

ArticleExperimental and clinical psychopharmacology2021

Establishing preclinical withdrawal syndrome symptomatology following heroin self-administration in male and female rats.

Cassandra D Gipson, Kelly E Dunn, Amanda Bull, Hanaa Ulangkaya, Aronee Hossain

Open access · hybridAbstract read
In one paragraph

Article in Experimental and clinical psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. An Investigation of the RNA Modification mInternational journal of molecular sciences · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Cassandra D GipsonDepartment of Family and Community Medicine, University of Kentucky.ORCID 0000-0003-2372-9323
Kelly E DunnBehavioral Pharmacology Research Unit, Johns Hopkins University.
Amanda BullDepartment of Psychology, Arizona State University.
Hanaa UlangkayaDepartment of Psychology, Arizona State University.ORCID 0000-0001-9212-8674
Aronee HossainDepartment of Psychology, Arizona State University.
Arizona State University · USJohns Hopkins University · USUniversity of Kentucky · US

Funding

Neuroinflammatory and glutamatergic mechanisms of nicotine seekingR01DA046526 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D · 2019 to 2023
$1.9M
Glutamergic Mechanisms in Opioid and Cocaine Co-UseR33DA049130 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D, STOOPS, WILLIAM WALTON · 2022 to 2024
$1.9M
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine RelapseR00DA036569 · NIDA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI GIPSON-REICHARDT, CASSANDRA D · 2016 to 2018
$836k
Cholinergic modulation of glutamatergic signaling in nicotine addiction and relapseR21DA044479 · NIDA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI GIPSON-REICHARDT, CASSANDRA D, OLIVE, M. FOSTER · 2018 to 2019
$461k
Glutamergic Mechanisms in Opioid and Cocaine Co-UseR21DA049130 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D, STOOPS, WILLIAM WALTON · 2020 to 2021
$402k
Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapseR41DA046266 · NIDA · NEUROP, INC. · PI ZACZEK, ROBERT · 2018 to 2018
$301k
Contributions of Glial Glutamate Transport and NMDA Receptors in Nicotine RelapseK99DA036569 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GIPSON-REICHARDT, CASSANDRA D · 2014 to 2015
$262k
Glutamatergic mechanisms underlying nicotine addiction and relapse following nicotine reductionR03DA045881 · NIDA · UNIVERSITY OF KENTUCKY · PI GIPSON-REICHARDT, CASSANDRA D · 2018 to 2019
$154k
Arizona Alzheimer's ConsortiumNIDA NIH HHS K99 DA036569NIDA NIH HHS R00 DA036569NIDA NIH HHS R01 DA046526NIDA NIH HHS R03 DA045881NIDA NIH HHS R21 DA044479NIDA NIH HHS R21 DA049130NIDA NIH HHS R33 DA049130NIDA NIH HHS R41 DA046266NIH HHS
6 · The paper itself

Abstract

Opioid use disorder (OUD) is a significant health problem, and understanding mechanisms of various aspects of OUD including drug use and withdrawal is important. Preclinical models provide an ideal opportunity to evaluate mechanisms underlying opioid withdrawal. Current models are limited by their reliance upon forced opioid administration, focus on the acute (and not protracted) syndrome, and exclusion of females. In this study, male and female rats self-administered heroin (maintenance dose of 12.5 μg/kg/infusion) and opioid withdrawal after abrupt discontinuation was measured. In Phase 1, acute withdrawal symptoms were rated in male and female rats at 0, 16, 48, and 72 hr after the last self-administration session. Total somatic signs increased until 48 hr (predominantly in females), and heroin intake positively correlated with total somatic signs at the 48 and 72 hr timepoints. Measures of hyperactivity and anxiety-like behavior increased by 16 and 48 hr, respectively. In Phase 2, symptoms were assessed at baseline, acute, and protracted (168 and 312 hr after self-administration) timepoints in a subset of male and female rats from Phase 1. The total number of somatic signs did not differ across timepoints, though females displayed significantly higher body temperature at all timepoints compared with males, indicating sex-specific protracted withdrawal symptomatology. These data provide a thorough characterization of rodent opioid withdrawal symptomatology after self-administration and abrupt discontinuation that serve as a foundation for future studies designed to mimic the human experience, and demonstrate the importance of characterizing acute and protracted withdrawal with sex-specificity in preclinical models of opioid self-administration. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Indexed as

Opioid-Related DisordersSubstance Withdrawal SyndromeAnimalsFemaleHeroinMaleNarcoticsRatsSelf AdministrationHeroinNarcotics

Identifiers

PMID32297787
PMCPMC8405057
OpenAlexW3016766819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.